GELNIQUE (oxybutynin chloride) by AbbVie is clinical pharmacology oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. First approved in 2009.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
GELNIQUE is a transdermal gel formulation of oxybutynin chloride, an anticholinergic agent that relaxes bladder smooth muscle by inhibiting muscarinic acetylcholine activity. It treats overactive bladder (OAB) characterized by involuntary detrusor contractions, reducing urgency, incontinence episodes, and urinary frequency. The R-isomer of oxybutynin provides the primary antimuscarinic effect, with a metabolite (desethyloxybutynin) contributing additional pharmacological activity.
Product is at peak commercial maturity with modest Part D spending ($816K, 1,113 claims in 2023), indicating stable but limited growth trajectory for a mature franchise.
CLINICAL PHARMACOLOGY Oxybutynin chloride exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to…
Worked on GELNIQUE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Oxybutynin Chloride in Managing Hot Flashes
An Efficacy and Safety Study of Oxybutynin Chloride Oral Osmotic Therapeutic System (OROS) in Korean Overactive Bladder Participants
The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~5 years — strategic planning for patent cliff underway
Working on GELNIQUE offers exposure to mature product lifecycle management and competitive positioning in a therapeutic area with high clinical relevance to aging populations. The product's peak-stage status and approaching loss of exclusivity (4.8 years remaining) present both stability and urgency—strong candidates should expect focus on market defense, pricing strategy, and transition planning rather than greenfield growth.